Business
Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment
Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ: NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment. “The acquisition of Inari Medical marks a sig
About this update from Stryker Corporation
[{"type":"image","alt":"Stryker Corporation","displaySize":"","headline":null,"caption":"Stryker Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":81,"url":"https://media.zenfs.com/en/globenewswire.com/7ec0eb9c6b87c94ad537dbc1f23e8c4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ysZHWev_ZxFHcibTRqVs_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExMztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/7ec0eb9c6b87c94ad537dbc1f23e8c4e","width":300,"height":81}},"lazy":false},{"type":"text","content":"Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ: NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment.","length":454,"tagName":"p"},{"type":"text","content":"“The acquisition of Inari Medical marks a significant milestone in expanding our interventional endovascular portfolio,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker. “We look forward to welcoming the talented Inari team to Stryker and working together to improve outcomes for patients worldwide.”","length":312,"tagName":"p"},{"type":"text","content":"Inari’s product portfolio is highly complementary to Stryker’s Neurovascular business and includes two novel mechanical thrombectomy solutions—the FlowTriever System for the treatment of pulmonary embolism and the ClotTriever System for thrombectomy in the peripheral vessels—as well as emerging therapies.","length":306,"tagName":"p"},{"type":"text","content":"Completion of Tender Offer and Merger The previously announced cash tender offer for all of the outstanding shares of common stock of Inari for $80.00 per share, net to the seller in cash, without interest and subject to any applicable tax withholding, by Eagle 1 Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of Stryker, expired at one minute after 11:59 p.m., Eastern Time, on February 18, 2025. Equiniti Trust Company, LLC, the depository for the tender offer, has advised Stryker that 48,504,444 Inari shares (excluding shares tendered by notice of guaranteed delivery for which c...